During the BIO-Europe conference in Stockholm, Optimum co-hosted a special reception featuring a fireside chat with Renée Aguiar-Lucander, former CEO of Calliditas, who led the Swedish company since 2017 until recently – taking it from small biotech to its $1.1 billion acquisition. Here, we tell the story of her remarkable seven-year journey with the firm. […]
By Richard Staines, Optimum Strategic Communications The re-election of Donald Trump as President of the Unites States represents a seismic shift in the U.S. political system, with huge ramifications for all policy areas including healthcare. But, at the time of writing, the identity of the next Secretary of the Department of Health and Human Services […]
Infinitopes, an integrated cancer biotech combining world leading platforms in precision antigen discovery with vaccine vectors capable of durably stimulating protective immune responses, on Friday announced that it will be presenting three posters on its pioneering cancer vaccine discovery and development, including one that has been recognised as a ‘top 100’ poster presentation, at the Society […]
At the Optimum Strategic Communications’ 16th Annual Healthcare Investor Conference, held on Thursday 10th October 2024 at The King’s Fund, London, Dr Mehmood Khan, CEO of the Hevolution Foundation, spoke to Clive Cookson, Senior Science Writer at the Financial Times, about investing in “healthspan”. What is “healthspan”? Unlike “lifespan” it isn’t an everyday term. Yet […]
Remarkable results from the start of a trial testing Ariceum Therapeutics’ experimental radiopharmaceutical drug ATT001 in patients with recurrent glioblastoma brain cancer generated strong coverage in the UK’s national media this week. Meanwhile Ariceum’s Chief Operating Officer Greg Mullen featured in an Optimum TV episode, where he explained the highly targeted radiopharmaceutical approach, called Auger […]
